Paper31316634
Anti-CD22 epratuzumab for systemic lupus erythematosus: A systematic review and meta-analysis of randomized controlled trials.
Li J and 5 others. Exp Ther Med, 2019. Cited by 11 papers, by iCite.
Cite this record
ConductScience Library. Anti-CD22 epratuzumab for systemic lupus erythematosus: A systematic review and meta-analysis of randomized controlled trials. Papers, record 31316634. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31316634
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Anti-CD22 epratuzumab for systemic lupus erythematosus: A systematic review and meta-analysis of randomized controlled trials.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References40
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 14506197 | Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. | Clin Cancer Res | 2003 | https://conductscience.org/library/papers/14506197 | PubMed |
| 2 | 14530779 | Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. | Medicine (Baltimore) | 2003 | https://conductscience.org/library/papers/14530779 | PubMed |
| 3 | 15840177 | Estimating the mean and variance from the median, range, and the size of a sample. | BMC Med Res Methodol | 2005 | https://conductscience.org/library/papers/15840177 | PubMed |
| 4 | 16630358 | Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. | Arthritis Res Ther | 2006 | https://conductscience.org/library/papers/16630358 | PubMed |
| 5 | 16864854 | Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. | J Clin Oncol | 2006 | https://conductscience.org/library/papers/16864854 | PubMed |
| 6 | 18305268 | Systemic lupus erythematosus. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18305268 | PubMed |
| 7 | 21258803 | Systemic lupus erythematosus in the elderly. | Rheumatol Int | 2012 | https://conductscience.org/library/papers/21258803 | PubMed |
| 8 | 22949364 | Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis. | J Zhejiang Univ Sci B | 2012 | https://conductscience.org/library/papers/22949364 | PubMed |
| 9 | 22983769 | Survival analysis of late-onset systemic lupus erythematosus: a cohort study in China. | Clin Rheumatol | 2012 | https://conductscience.org/library/papers/22983769 | PubMed |
| 10 | 23083346 | CD22 and autoimmune disease. | Int Rev Immunol | 2012 | https://conductscience.org/library/papers/23083346 | PubMed |
| 11 | 23313811 | Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. | Ann Rheum Dis | 2014 | https://conductscience.org/library/papers/23313811 | PubMed |
| 12 | 23542611 | Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. | Rheumatology (Oxford) | 2013 | https://conductscience.org/library/papers/23542611 | PubMed |
| 13 | 23553783 | Epratuzumab for systemic lupus erythematosus. | Lupus | 2013 | https://conductscience.org/library/papers/23553783 | PubMed |
| 14 | 23612795 | Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature. | Lupus | 2013 | https://conductscience.org/library/papers/23612795 | PubMed |
| 15 | 23821660 | Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. | Blood | 2013 | https://conductscience.org/library/papers/23821660 | PubMed |
| 16 | 24160940 | Anti-B cell antibody therapies for inflammatory rheumatic diseases. | Annu Rev Med | 2014 | https://conductscience.org/library/papers/24160940 | PubMed |
| 17 | 24190520 | Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis. | BioDrugs | 2014 | https://conductscience.org/library/papers/24190520 | PubMed |
| 18 | 24212677 | Association between vitamin D receptor gene BsmI, FokI, ApaI and TaqI polymorphisms and the risk of systemic lupus erythematosus: a meta-analysis. | Rheumatol Int | 2014 | https://conductscience.org/library/papers/24212677 | PubMed |
| 19 | 24504808 | The incidence and prevalence of systemic lupus erythematosus, 2002-2004: The Georgia Lupus Registry. | Arthritis Rheumatol | 2014 | https://conductscience.org/library/papers/24504808 | PubMed |
| 20 | 24773152 | Epratuzumab for systemic lupus erythematosus. | Expert Opin Biol Ther | 2014 | https://conductscience.org/library/papers/24773152 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40533299 | Exploring the depths of hypogammaglobulinemia in lymphoid malignancies: Pathophysiology, clinical implications, management options, and future directions. | Blood Rev | 2025 | https://conductscience.org/library/papers/40533299 | PubMed |
| 39749335 | CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives. | Front Immunol | 2024 | https://conductscience.org/library/papers/39749335 | PubMed |
| 38817250 | A high-throughput lysosome trafficking assay guides ligand selection and elucidates differences in CD22-targeted nanodelivery. | Sci Technol Adv Mater | 2024 | https://conductscience.org/library/papers/38817250 | PubMed |
| 38050332 | Model-based meta-analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus. | CPT Pharmacometrics Syst Pharmacol | 2024 | https://conductscience.org/library/papers/38050332 | PubMed |
| 33948430 | Exploring the role of immunotherapeutic drugs in autoimmune diseases: A comprehensive review. | J Oral Biol Craniofac Res | 2021 | https://conductscience.org/library/papers/33948430 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CD22 | 933 | PubTator's text mining | https://conductscience.org/library/genes/933 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31316634
GET https://conductscience.org/api/papers/v1/31316634/references?page=2